Zhengye Biotechnology Holding Ltd. (ZYBT)
NASDAQ:ZYBT
Want to see ZYBT full AI Analyst Report?
ZYBT Stock Chart & Stats
$1.13
--
Market closed
$1.13
--
Day’s Range― - ―
52-Week Range$0.68 - $13.79
Previous CloseN/A
VolumeN/A
Average Volume (3M)871.70K
Market Cap
$10.80M
Enterprise Value$24.75M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta-0.46
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding10,965,000
10 Day Avg. Volume198,467
30 Day Avg. Volume871,704
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap2.29
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Moderate Leverage And Sizable EquityA debt-to-equity ratio near 0.30 combined with roughly $249.8M of equity provides a durable capital cushion. Moderate leverage preserves financial flexibility to fund operations, R&D or restructuring through a loss cycle, keeping solvency risk manageable over months.
Positive Operating Cash FlowMaintaining positive operating cash flow ($13.3M in 2025) despite a net loss indicates the core business can still generate cash. That cash-generation provides near-term liquidity to fund working capital and gives management runway to implement operational fixes without immediate reliance on external financing.
Governance & Capital Structure Changes ApprovedShareholder approval of new directors, reclassification and consolidation are structural changes that expand strategic flexibility and enable governance refresh. These actions can facilitate remediation of regulatory issues and provide tools for future capital or structural initiatives over the medium term.
Bears Say
Sharp Revenue Decline And Margin CollapseA drop from $186.4M to $116.4M and a swing to roughly -60% net margin in 2025 reflect a deep, multi-year demand or pricing deterioration. Sustained revenue contraction and margin erosion materially reduce internal reinvestment capacity and pressure the viability of the current business model over coming quarters.
Weak And Volatile Free Cash FlowOperating cash flow declined sharply and free cash flow collapsed to near zero, creating an unstable cash base. Persistent volatility and diminished FCF weaken the company's ability to fund R&D, service obligations or weather further revenue shocks without tapping external capital, increasing financing risk.
Board Independence And Nasdaq Compliance GapLoss of a majority of independent directors and a Nasdaq independence deficiency is a structural governance risk. Regulatory non-compliance can threaten listing status, distract management, harm investor confidence, and limit capital market access until independence and committee composition are robustly restored.
Zhengye Biotechnology Holding Ltd. News
ZYBT FAQ
What was Zhengye Biotechnology Holding Ltd.’s price range in the past 12 months?
Zhengye Biotechnology Holding Ltd. lowest stock price was $0.68 and its highest was $13.79 in the past 12 months.
What is Zhengye Biotechnology Holding Ltd.’s market cap?
Zhengye Biotechnology Holding Ltd.’s market cap is $10.80M.
When is Zhengye Biotechnology Holding Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Zhengye Biotechnology Holding Ltd.’s earnings last quarter?
Currently, no data Available
Is Zhengye Biotechnology Holding Ltd. overvalued?
According to Wall Street analysts Zhengye Biotechnology Holding Ltd.’s price is currently Overvalued.
Does Zhengye Biotechnology Holding Ltd. pay dividends?
Zhengye Biotechnology Holding Ltd. does not currently pay dividends.
What is Zhengye Biotechnology Holding Ltd.’s EPS estimate?
Zhengye Biotechnology Holding Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Zhengye Biotechnology Holding Ltd. have?
Zhengye Biotechnology Holding Ltd. has 10,965,000 shares outstanding.
What happened to Zhengye Biotechnology Holding Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Zhengye Biotechnology Holding Ltd.?
Currently, no hedge funds are holding shares in ZYBT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Zhengye Biotechnology Holding Ltd.
Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in China. It offers vaccines for swine, cattle, goats, sheep, poultry, and dogs. The company also exports its products to Vietnam, Pakistan, and Egypt. The company was founded in 2004 and is based in Jilin, China. Zhengye Biotechnology Holding Limited operates as a subsidiary of Securingium Holding Limited.
Technical Analysis
China Pharma Holdings
―
China SXT Pharmaceuticals
―
Qilian International Holding Group Limited
―
Universe Pharmaceuticals
―
Shuttle Pharmaceuticals Holdings, Inc.
―
Ownership Overview
―
Insiders
0.27% Mutual Funds
0.58% Other Institutional Investors
99.16% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---